Our previous study reported that ZY0511, a potent and novel small molecular LSD1 inhibitor, exhibited a strong anti‐tumor efficiency against CRC and cervical cancer both in vitro and in vivo and is well tolerated.20, 21, 22. This evidence concerns the gene KDM1A and colorectal carcinoma.